^
    Back
    Association details:
    Biomarker:HR positive
    Cancer:HER2 Negative Breast Cancer
    Drug:praluzatamab ravtansine (CX-2009) (Microtubule inhibitor, CD166-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    SABCS 2022
    Title:

    Preliminary results from a phase 2 study of praluzatamab ravtansine (CX-2009) in patients with advanced breast cancer (ABC)

    Published date:
    11/22/2022
    Excerpt:
    Arm A met the primary efficacy endpoint with a confirmed ORR by central radiology of 14.9% (n=47); by investigator, ORR was similar at 15.4% (n=52)...Praluzatamab ravtansine demonstrated single-agent activity in unselected heavily pretreated patients with HR+/HER2- ABC
    Trial ID:
    CTMX-2009-002
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    Praluzatamab ravtansine, a CD166-targeting antibody-drug conjugate, in patients with advanced solid tumors: an open-label phase 1/2 trial

    Published date:
    02/14/2022
    Excerpt:
    CX-2009 was evaluated in a phase 1/2 clinical trial for patients with advanced solid tumors....Tumor regressions were observed at doses {greater than or equal to}4 mg/kg. In the HR-positive/HER2-non-amplified BC subset (n=22), two patients (9%) had confirmed partial responses, and 10 patients (45%) had stable disease.
    DOI:
    10.1158/1078-0432.CCR-21-3656